SpringerOpen Newsletter

Receive periodic news and updates relating to SpringerOpen.

Open Access Nano Express

Structural damage of chicken red blood cells exposed to platinum nanoparticles and cisplatin

Marta Kutwin1, Ewa Sawosz1, Sławomir Jaworski1, Natalia Kurantowicz1, Barbara Strojny1 and André Chwalibog2*

Author Affiliations

1 Division of Biotechnology and Biochemistry of Nutrition, Faculty of Animal Science, Warsaw University of Life Science, Warsaw 02-786, Poland

2 Department of Veterinary Clinical and Animal Sciences, University of Copenhagen, Groennegaardsvej 3, Frederiksberg, Copenhagen 1870, Denmark

For all author emails, please log on.

Nanoscale Research Letters 2014, 9:257  doi:10.1186/1556-276X-9-257

Published: 23 May 2014

Abstract

Side effects and resistance of cancer cells to cisplatin are major drawbacks to its application, and recently, the possibility of replacing cisplatin with nanocompounds has been considered. Most chemotherapeutic agents are administered intravenously, and comparisons between the interactions of platinum nanoparticles (NP-Pt) and cisplatin with blood compartments are important for future applications. This study investigated structural damage, cell membrane deformation and haemolysis of chicken embryo red blood cells (RBC) after treatment with cisplatin and NP-Pt. Cisplatin (4 μg/ml) and NP-Pt (2,6 μg/ml), when incubated with chicken embryo RBC, were detrimental to cell structure and induced haemolysis. The level of haemolytic injury was increased after cisplatin and NP-Pt treatments compared to the control group. Treatment with cisplatin caused structural damage to cell membranes and the appearance of keratocytes, while NP-Pt caused cell membrane deformations (discoid shape of cells was lost) and the formation of knizocytes and echinocytes. This work demonstrated that NP-Pt have potential applications in anticancer therapy, but potential toxic side effects must be explored in future preclinical research.

Keywords:
Platinum nanoparticles; Cisplatin; Haemolysis; Red blood cells; Cancer therapy